Tapentadol immediate-release for acute pain.
Tapentadol is a novel opioid agent with a dual mode of analgesic action. The inhibition of norepinephrine combined with moderate opioid agonist activity results in fewer gastrointestinal adverse effects compared with equianalgesic doses of oxycodone. Having no active metabolites and minimal protein binding, tapentadol provides improved tolerability with a lower potential for pharmacokinetic drug-drug interactions or accumulation with impaired renal or hepatic function when compared with oxycodone. Tapentadol immediate-release is currently US FDA approved for moderate-to-severe acute pain in adults.
Hartrick
Craig T
CT
Anesthesiology Research, Oakland University William Beaumont School of Medicine, 3601 W. 13 Mile Rd., Royal Oak, MI 48073, USA. chartrick@beaumont.edu
D002986:Clinical Trials as Topic; D004347:Drug Interactions; D006801:Humans; D010146:Pain / Q000188:drug therapy*; D010636:Phenols / Q000008:administration & dosage* / Q000627:therapeutic use; D017450:Receptors, Opioid, mu / Q000819:agonists*; D000077432:Tapentadol; D016896:Treatment Outcome
D010636:Phenols; D017450:Receptors, Opioid, mu; D000077432:Tapentadol